Y Intercept Hong Kong Ltd Purchases 46,140 Shares of Xencor, Inc. $XNCR

Y Intercept Hong Kong Ltd grew its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 93.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 95,745 shares of the biopharmaceutical company’s stock after acquiring an additional 46,140 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.13% of Xencor worth $753,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XNCR. Braidwell LP boosted its position in shares of Xencor by 169.0% during the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company’s stock valued at $17,617,000 after acquiring an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA boosted its position in shares of Xencor by 8.6% during the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock valued at $103,857,000 after acquiring an additional 776,580 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Xencor during the 1st quarter valued at approximately $4,860,000. BVF Inc. IL boosted its position in shares of Xencor by 19.7% during the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock valued at $29,155,000 after acquiring an additional 451,381 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Xencor by 73.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 904,485 shares of the biopharmaceutical company’s stock valued at $9,624,000 after acquiring an additional 384,509 shares during the last quarter.

Xencor Stock Up 4.9%

XNCR stock opened at $14.37 on Thursday. The business’s fifty day simple moving average is $11.47 and its two-hundred day simple moving average is $9.64. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $27.24. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -5.99 and a beta of 0.96.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $29.73 million. During the same quarter last year, the firm posted ($0.71) earnings per share. The business’s revenue was up 18.0% compared to the same quarter last year. Research analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Tuesday, October 14th. Wells Fargo & Company dropped their price objective on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Royal Bank Of Canada boosted their price objective on shares of Xencor from $15.00 to $18.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Barclays raised shares of Xencor from an “underweight” rating to an “overweight” rating and increased their target price for the company from $6.00 to $23.00 in a research note on Wednesday, October 29th. Finally, Bank of America downgraded shares of Xencor from a “buy” rating to a “neutral” rating and reduced their target price for the company from $23.00 to $12.00 in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.44.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.